Sustained API pricing pressure
API business continues to face pricing softness across key molecules, though the pace of decline has moderated.
AKUMSDRUGSPHARMACEUTICAL / bear-case history
Track the concerns that keep returning.
Akums Drugs & · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Potential delays in regulatory approvals for new facilities
The injectables facility is still ramping up with low utilization; delays in client audits or approvals could impact revenue contribution.
Trade generic segment losses may persist
Trade generic revenue declined 18% YoY and remains loss-making; management expects some bottom-line impact in Q4.
Dependence on CDMO volume growth sustainability
Analyst questioned whether the strong volume growth is sustainable; management cited market share gains but acknowledged it's market-driven.
Sustained API price weakness
API prices remain lower than last year despite recent uptick; further decline could delay turnaround and keep losses elevated.
Execution risk in Zambia and European contracts
Delays in regulatory approvals or tech transfer could push back revenue recognition from these large contracts.
GLP-1 market entry uncertainty
Management was evasive on GLP-1 strategy, citing pricing volatility; missing this opportunity could limit future growth.
Working capital increase
Working capital days rose from 91 to 105 due to inventory buildup; further increases could pressure cash flows.